OutPost Bio
OutPost Bio combines advanced bioinformatics and AI models to analyse large-scale genomic and proteomic datasets, identifying new oncological targets and predictive biomarkers.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – March 5, 2026
Listen to the episodeAbout OutPost Bio
OutPost Bio is a British computational biology startup founded in 2025 identifying new cancer therapeutic targets through AI applied to genomic, transcriptomic and proteomic datasets. In March 2026 it raised EUR 2.9M in pre-seed.
Market & Clients
Key Customers
Pharmaceutical and biotech companies seeking to accelerate oncological target discovery with bioinformatics AI platforms.
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Pre-Seed: euro2M
Similar Startups
Isomorphic Labs
Isomorphic Labs applies advanced AI models — including those underlying AlphaFold — to drug discovery and design, aiming to transform molecular biology into a computational process and radically accelerate therapeutic pipelines.
Read AnalysisCHARM Therapeutics
CHARM Therapeutics uses DragonFold, a 3D deep learning-based protein-ligand prediction AI platform, to identify and validate therapeutic molecules with high specificity against complex protein targets.
Read Analysis